Last reviewed · How we verify

Carbamazepine (Tegretol)

Korean Epilepsy Society · FDA-approved active Small molecule

Carbamazepine (Tegretol) is a Anticonvulsant; sodium channel blocker Small molecule drug developed by Korean Epilepsy Society. It is currently FDA-approved for Epilepsy (generalized tonic-clonic and partial seizures), Trigeminal neuralgia, Bipolar disorder (acute mania and maintenance). Also known as: Tegretol, Carbamazepine (Tegretol-XR) placebo..

Carbamazepine stabilizes neuronal membranes and reduces repetitive neuronal firing by blocking voltage-gated sodium channels.

Carbamazepine stabilizes neuronal membranes and reduces repetitive neuronal firing by blocking voltage-gated sodium channels. Used for Epilepsy (generalized tonic-clonic and partial seizures), Trigeminal neuralgia, Bipolar disorder (acute mania and maintenance).

At a glance

Generic nameCarbamazepine (Tegretol)
Also known asTegretol, Carbamazepine (Tegretol-XR) placebo.
SponsorKorean Epilepsy Society
Drug classAnticonvulsant; sodium channel blocker
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaNeurology
PhaseFDA-approved

Mechanism of action

The drug binds to inactivated sodium channels in the brain, preventing their reopening and thereby reducing the frequency of action potentials. This membrane-stabilizing effect suppresses abnormal electrical activity in the central nervous system, making it effective for controlling seizures and neuropathic pain. It also has mild anticholinergic and antidiuretic properties.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Carbamazepine (Tegretol)

What is Carbamazepine (Tegretol)?

Carbamazepine (Tegretol) is a Anticonvulsant; sodium channel blocker drug developed by Korean Epilepsy Society, indicated for Epilepsy (generalized tonic-clonic and partial seizures), Trigeminal neuralgia, Bipolar disorder (acute mania and maintenance).

How does Carbamazepine (Tegretol) work?

Carbamazepine stabilizes neuronal membranes and reduces repetitive neuronal firing by blocking voltage-gated sodium channels.

What is Carbamazepine (Tegretol) used for?

Carbamazepine (Tegretol) is indicated for Epilepsy (generalized tonic-clonic and partial seizures), Trigeminal neuralgia, Bipolar disorder (acute mania and maintenance), Neuropathic pain.

Who makes Carbamazepine (Tegretol)?

Carbamazepine (Tegretol) is developed and marketed by Korean Epilepsy Society (see full Korean Epilepsy Society pipeline at /company/korean-epilepsy-society).

Is Carbamazepine (Tegretol) also known as anything else?

Carbamazepine (Tegretol) is also known as Tegretol, Carbamazepine (Tegretol-XR) placebo..

What drug class is Carbamazepine (Tegretol) in?

Carbamazepine (Tegretol) belongs to the Anticonvulsant; sodium channel blocker class. See all Anticonvulsant; sodium channel blocker drugs at /class/anticonvulsant-sodium-channel-blocker.

What development phase is Carbamazepine (Tegretol) in?

Carbamazepine (Tegretol) is FDA-approved (marketed).

What are the side effects of Carbamazepine (Tegretol)?

Common side effects of Carbamazepine (Tegretol) include Dizziness, Ataxia, Diplopia, Nausea, Rash (including Stevens-Johnson syndrome), Hyponatremia.

What does Carbamazepine (Tegretol) target?

Carbamazepine (Tegretol) targets Voltage-gated sodium channels and is a Anticonvulsant; sodium channel blocker.

Related